Results of observational study published in Genetics in Medicine.
DANVILLE, Pa. – A team of Geisinger researchers has found that genomic screening programs, like Geisinger’s MyCode Community Health Initiative, can identify previously undiagnosed individuals with an increased risk of cancer and heart disease, facilitating risk management and early cancer detection.
The research team conducted an observational study of participants enrolled in MyCode, which returns medically actionable results, including an individual’s increased genetic risk for hereditary breast and ovarian cancers, Lynch syndrome and familial hypercholesterolemia. These conditions are among those recognized by the CDC as having “tier 1” evidence for interventions that reduce morbidity and mortality in people with increased genetic risk.
The team found that 87% of study participants with a tier 1 gene variant did not have a prior diagnosis of the related condition. More than 70 percent of individuals who were notified of their genetic result then had a recommended procedure, such as a colonoscopy or lipid panel, following the notification. This evidence suggests that genomic screening programs are an effective way to identify individuals who could benefit from early intervention and risk management but have not yet been diagnosed, and encourage these individuals to take measures to reduce their risk, researchers said.
Results of the study were published in Genetics in Medicine.
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen